



## Therapeutic Antibodies against Virus Infection

Guest Editors:

**Dr. Adalbert Krawczyk**

Department of Infectious  
Diseases, West German Centre of  
Infectious Diseases, University  
Duisburg-Essen, Essen, Germany

**Dr. Matthias Zehner**

Laboratory of Experimental  
Immunology, Institute of  
Virology, Faculty of Medicine and  
University Hospital Cologne,  
University of Cologne, Cologne,  
Germany

Deadline for manuscript  
submissions:

**closed (31 August 2023)**

### Message from the Guest Editors

Dear Colleagues,

Therapeutic monoclonal antibodies (mAbs) have become one of the fastest-growing classes of drugs in recent years and are approved for the treatment of a wide range of indications, including virus infections. Mabs and polyclonal antibodies are used for pre-exposure prophylaxis (Prep), post-exposure prophylaxis (PEP), and treatment of viral infections such as rabies, hepatitis B, SARS-CoV-2, RSV, and others.

Commonly, antibody-based immunotherapies are well-tolerated, highly specific, and thus potent tools to protect from infection or a severe course of disease.

Development, characterization, and pre-clinical or clinical evaluation of novel antiviral mAbs that can protect from disease is important, and articles on this topic are welcome.

Dr. Adalbert Krawczyk

Dr. Matthias Zehner

*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### Dr. Eric O. Freed

Director, HIV Dynamics and  
Replication Program, Center for  
Cancer Research, National  
Cancer Institute, Frederick, MD  
21702-1201, USA

## Message from the Editor-in-Chief

*Viruses* (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, AGRIS, and other databases.**

**Journal Rank:** JCR - Q2 (*Virology*) / CiteScore - Q1 (Infectious Diseases)

## Contact Us

---

Viruses Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/viruses](http://mdpi.com/journal/viruses)  
[viruses@mdpi.com](mailto:viruses@mdpi.com)  
[X@VirusesMDPI](https://twitter.com/VirusesMDPI)